MA52411A - Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales - Google Patents

Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales

Info

Publication number
MA52411A
MA52411A MA052411A MA52411A MA52411A MA 52411 A MA52411 A MA 52411A MA 052411 A MA052411 A MA 052411A MA 52411 A MA52411 A MA 52411A MA 52411 A MA52411 A MA 52411A
Authority
MA
Morocco
Prior art keywords
medical uses
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
medical
Prior art date
Application number
MA052411A
Other languages
English (en)
Other versions
MA52411B1 (fr
Inventor
Ludwig Paul Cooymans
Werner Constant Johan Embrechts
Jérôme Émile Georges Guillemont
Tim Hugo Maria Jonckers
Gowan David Craig Mc
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA52411A publication Critical patent/MA52411A/fr
Publication of MA52411B1 publication Critical patent/MA52411B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA52411A 2018-03-01 2019-02-28 Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies MA52411B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18159583 2018-03-01
PCT/EP2019/054941 WO2019166532A1 (fr) 2018-03-01 2019-02-28 Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales

Publications (2)

Publication Number Publication Date
MA52411A true MA52411A (fr) 2021-01-06
MA52411B1 MA52411B1 (fr) 2022-12-30

Family

ID=61557126

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52411A MA52411B1 (fr) 2018-03-01 2019-02-28 Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies

Country Status (32)

Country Link
US (2) US11597704B2 (fr)
EP (2) EP3759083B1 (fr)
JP (1) JP2021514981A (fr)
KR (1) KR20200128394A (fr)
CN (1) CN111868040A (fr)
AR (1) AR114420A1 (fr)
AU (1) AU2019226342B2 (fr)
BR (1) BR112020017702A2 (fr)
CA (1) CA3091076A1 (fr)
CL (3) CL2020002253A1 (fr)
CY (1) CY1125489T1 (fr)
DK (1) DK3759083T3 (fr)
EA (1) EA202092052A1 (fr)
ES (1) ES2923579T3 (fr)
HR (1) HRP20220781T1 (fr)
HU (1) HUE059149T2 (fr)
IL (2) IL305388A (fr)
JO (2) JOP20200208B1 (fr)
LT (1) LT3759083T (fr)
MA (1) MA52411B1 (fr)
MD (1) MD3759083T2 (fr)
MX (2) MX2020009071A (fr)
PH (1) PH12020551345A1 (fr)
PL (1) PL3759083T3 (fr)
PT (1) PT3759083T (fr)
RS (1) RS63401B1 (fr)
SG (1) SG11202008293YA (fr)
SI (1) SI3759083T1 (fr)
SM (1) SMT202200315T1 (fr)
TW (2) TW202415645A (fr)
UA (1) UA127590C2 (fr)
WO (1) WO2019166532A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7336191B2 (ja) 2015-08-07 2023-08-31 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
TW202415645A (zh) * 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
KR102903509B1 (ko) * 2019-01-14 2025-12-22 인네이트 튜머 이뮤니티, 인코포레이티드 암의 치료에 사용하기 위한 nlrp3-조정제로서의 치환된 퀴나졸린
US20220241402A1 (en) * 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
EP4019517A4 (fr) 2019-08-19 2023-01-18 Shanghai Zhimeng Biopharma, Inc. Composés de 2-aminopyrimidine, compositions pharmaceutiques et utilisations associées
CN114555565B (zh) * 2019-12-13 2024-03-05 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
MX2022008286A (es) 2020-01-02 2022-08-08 Jiangsu Hengrui Medicine Co Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma.

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012964A (en) 1958-06-24 1961-12-12 Universal Oil Prod Co Hydrocarbon oil composition
US3022077A (en) 1958-09-15 1962-02-20 Doonan William Arrowhead construction
JP2610889B2 (ja) 1987-09-03 1997-05-14 日本臓器製薬株式会社 新規架橋アデニン誘導体
TW552261B (en) 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
CN1083841C (zh) 1996-10-04 2002-05-01 杏林制药株式会社 吡唑并吡啶基哒嗪酮衍生物及其制备方法
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
US6329381B1 (en) 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
JP4315300B2 (ja) 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
DE69917469T2 (de) 1998-08-27 2005-05-12 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidin derivate
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
CA2323008C (fr) 1999-10-11 2005-07-12 Pfizer Inc. Composes pharmaceutiques actifs
WO2002088079A2 (fr) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
JP4768263B2 (ja) 2002-09-27 2011-09-07 大日本住友製薬株式会社 新規アデニン化合物及びその用途
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
AU2004257149A1 (en) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
CN1938307B (zh) 2004-03-26 2010-06-16 大日本住友制药株式会社 9-取代的8-氧代腺嘌呤
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
WO2007084413A2 (fr) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Procedes de traitement de l’hepatite c
JP5031564B2 (ja) 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
WO2006050843A1 (fr) 2004-11-09 2006-05-18 F. Hoffmann-La Roche Ag Composes aminoquinazolines
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
CN101203519A (zh) 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2－酰氨基－6－氨基－8－氧代嘌呤衍生物
EP1877411B9 (fr) 2005-05-05 2012-08-29 Ardea Biosciences, Inc. Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih
AR054122A1 (es) 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
ES2612890T3 (es) 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20070099941A1 (en) 2005-11-02 2007-05-03 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1970373A1 (fr) 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Compose heterocyclique alicyclique
BRPI0707945A2 (pt) 2006-02-17 2011-05-17 Pfizer Ltd derivados de 3-deazapurina como modulares de tlr7
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés quinazoline 4,6-disubstitués et 2,4,6-trisubstitués et compositions pharmaceutiques utiles pour traiter des infections virales
ES2571028T3 (es) 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
CA2672250C (fr) 2006-12-20 2013-04-30 Ian Stansfield Indoles antiviraux
DK2510946T3 (en) 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
ES2457316T3 (es) 2007-03-19 2014-04-25 Astrazeneca Ab Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7)
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2138497A4 (fr) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Nouveau composé d'adénine
US9150556B2 (en) 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
EP2170888B1 (fr) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Dérivés de purine et leur utilisation comme modulateurs du récepteur de type toll-7
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
US8440681B2 (en) 2007-08-28 2013-05-14 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009030998A1 (fr) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés pyrimidine utilisés comme agonistes du récepteur de type toll (tlr)
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
CN101910177B (zh) 2007-12-24 2013-08-28 泰博特克药品公司 作为丙型肝炎病毒抑制剂的大环吲哚
MX2010008697A (es) 2008-02-07 2010-12-07 Univ California Tratamiento de enfermedades de la vejiga con un activador de tlr7.
EP2271345B1 (fr) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase hcv ns3
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
WO2010014913A1 (fr) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Formulations d'agoniste des récepteurs de type toll et leur utilisation
JP5913093B2 (ja) 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
ES2644286T3 (es) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
BR112013007678A2 (pt) 2010-10-01 2017-07-04 Ventirx Pharmaceuticals Inc método para tratamento de doenças alérgicas
WO2012066335A1 (fr) 2010-11-19 2012-05-24 Astrazeneca Ab Composés phénol en tant qu'agonistes du récepteur 7 de type toll
WO2012067269A1 (fr) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies
SI3590928T1 (sl) * 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
US8916575B2 (en) * 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
EA036645B1 (ru) 2011-11-09 2020-12-03 Янссен Сайенсиз Айрлэнд Юси Производные пурина для лечения вирусных инфекций
EP2812331B1 (fr) 2012-02-08 2019-01-02 Janssen Sciences Ireland Unlimited Company Dérivés de la pipéridino-pyrimidine pour le traitement des infections virales
CN106977495B (zh) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 Dna-pk抑制剂
MY167797A (en) 2012-07-13 2018-09-26 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
CN104781239B (zh) 2012-08-10 2019-03-01 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
CN104902885A (zh) 2012-08-28 2015-09-09 爱尔兰詹森科学公司 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
EP2712866A1 (fr) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) Dérivés de 1,2,4-triazine pour le traitement d'infections virales
CA2882786C (fr) 2012-10-05 2020-10-20 Janssen Sciences Ireland Uc Derives d'acylaminopyrimidine pour le traitement d'infections virales et d'autres maladies.
EP2906563B1 (fr) 2012-10-10 2018-02-28 Janssen Sciences Ireland UC Dérivés de pyrrolo[3,2-d] pyrimidine pour le traitement d'infections virales et d'autres maladies
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
HRP20170654T1 (hr) 2013-03-29 2017-06-30 Janssen Sciences Ireland Uc Makrociklički deaza-purinoni za liječenje virusnih infekcija
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2014187932A1 (fr) 2013-05-24 2014-11-27 Janssen R&D Ireland Dérivés de pyridone pour le traitement d'infections virales et d'autres maladies
CA2913028C (fr) * 2013-06-27 2022-03-08 Janssen Sciences Ireland Uc Derives de pyrrolo[3,2-d]pyrimidine pour le traitement des infections virales et autres maladies
JP6401788B2 (ja) 2013-07-30 2018-10-10 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体
US9701661B2 (en) 2014-07-11 2017-07-11 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CU20180011A7 (es) * 2015-03-04 2018-06-05 Gilead Sciences Inc Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
AR107633A1 (es) 2016-02-19 2018-05-16 Hoffmann La Roche Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
MX2018012557A (es) 2016-04-15 2019-07-04 Janssen Sciences Ireland Uc Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside.
WO2018002319A1 (fr) * 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines pour le traitement d'infections virales
PL3507276T3 (pl) * 2016-09-02 2022-02-21 Gilead Sciences, Inc. Związki modulatory receptorów toll-podobnych
TW202415645A (zh) * 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途

Also Published As

Publication number Publication date
IL276952B2 (en) 2024-02-01
ES2923579T3 (es) 2022-09-28
CN111868040A (zh) 2020-10-30
JOP20230207A1 (ar) 2023-09-05
CY1125489T1 (el) 2025-05-09
HUE059149T2 (hu) 2022-10-28
RS63401B1 (sr) 2022-08-31
DK3759083T3 (da) 2022-08-01
SMT202200315T1 (it) 2022-09-14
PH12020551345A1 (en) 2021-09-06
EP3759083A1 (fr) 2021-01-06
JOP20200208A1 (ar) 2020-08-30
JOP20200208B1 (ar) 2024-04-18
CL2021001753A1 (es) 2021-12-17
TW202415645A (zh) 2024-04-16
EP4059924A1 (fr) 2022-09-21
MA52411B1 (fr) 2022-12-30
JP2021514981A (ja) 2021-06-17
NZ768393A (en) 2024-10-25
US20210040046A1 (en) 2021-02-11
US20230278964A1 (en) 2023-09-07
PT3759083T (pt) 2022-07-05
IL276952B1 (en) 2023-10-01
IL305388A (en) 2023-10-01
UA127590C2 (uk) 2023-10-25
TW201945003A (zh) 2019-12-01
MD3759083T2 (ro) 2022-09-30
EP3759083B1 (fr) 2022-05-04
WO2019166532A1 (fr) 2019-09-06
AU2019226342B2 (en) 2024-02-15
PL3759083T3 (pl) 2022-08-29
CA3091076A1 (fr) 2019-09-06
SI3759083T1 (sl) 2022-08-31
AU2019226342A1 (en) 2020-08-13
LT3759083T (lt) 2022-07-11
CL2020002253A1 (es) 2021-01-15
KR20200128394A (ko) 2020-11-12
AR114420A1 (es) 2020-09-02
CL2022000125A1 (es) 2022-10-07
HRP20220781T1 (hr) 2022-09-30
IL276952A (en) 2020-10-29
MX2020009071A (es) 2020-10-08
SG11202008293YA (en) 2020-09-29
BR112020017702A2 (pt) 2020-12-22
EA202092052A1 (ru) 2020-12-07
MX2023001803A (es) 2023-03-10
US11597704B2 (en) 2023-03-07

Similar Documents

Publication Publication Date Title
MA52483A (fr) Dérivés de gip et leurs utilisations
MA52411A (fr) Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales
EP3829649A4 (fr) Complexes de ciblage musculaire et leurs utilisations
EP3706762A4 (fr) N4-hydroxycytidine et dérivés et leurs utilisations anti-virales
EP3841096A4 (fr) Dérivés de pyridinylméthylènepipéridine et leurs utilisations
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
EP3297637A4 (fr) Dérivés de benzène-1,3,5-tricarboxamide et utilisations de ces dérivés
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA49952A (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
EP3958861A4 (fr) Dégradeurs de la kinase cycline-dépendante 12 (cdk12) et leurs utilisations
MA52365A (fr) Composés et leurs utilisations
EP3559000A4 (fr) Dérivés de benzimidazole, leurs procédés de préparation et leurs utilisations
EP3768269A4 (fr) Composés et leurs utilisations
MA54051A (fr) Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations
EP4017843A4 (fr) Dérivés de benzènesulfonamide et leurs utilisations
EP3846807A4 (fr) Composés d'imidazoquinoléine et leurs utilisations
EP3399978A4 (fr) Composés antiprolifératifs, leurs compositions pharmaceutiques et leurs utilisations
MA50413A (fr) Dérivés de benzimidazole et leurs utilisations
EP3347006A4 (fr) Analogues deutérés d'étifoxine, leurs dérivés et leurs utilisations
EP3638251A4 (fr) Formulations de gel de bisphosphocine et leurs utilisations
EP3303366A4 (fr) Dérivés de dolastatine 10 et utilisations de ceux-ci
EP3323817A4 (fr) Dérivés d'aniline pyrimidine et leurs utilisations
EP3853216A4 (fr) Composés substitués par pyridinyle et leurs utilisations
EP3526215A4 (fr) Dérivés de n-acyléthanolamide et leurs utilisations
MA52976A (fr) Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations